BRAF and metastatic melanoma: Clinical trials of the triple combination of PD-L1 antibody, atezolizumab, BRAF inhibitor, vemurafenib and MEK inhibitor, cobimetinib result in significantly prolonged progression-free survival compared with the combination of vemurafenib and cobimetinib (15.1 months vs 10.6 months), and manageable toxicity.620,621 Based on the favorable results of the triplet combination, the FDA-approved atezolizumab in combination with cobimetinib and vemurafenib for patients with BRAFV600 mutated unresectable or metastatic melanoma in 2020.